Glenmark Pharmaceuticals has informed that the Operations Committee of the Board of Directors of the Company, at its Meeting held on February 25, 2014 allotted 3,600 shares to the employees of the company on exercise of options granted to them pursuant to ESOS 2003.
The above information is a part of company’s filings submitted to BSE.